Business & Finance
CellaVision's profit up in 2017
12 February 2018 -

Medical technology company CellaVision AB (STO:CEVI) on Friday reported profit before tax of SEK90.3m, or EPS of SEK2.92, for 2017, from 1 January 2017 to 31 December 2017.

This was an increase over profit before tax of SEK75.8m, or EPS of SEK2.51, in 2016.

Net sales for the year were up by 17% to SEK309.3m, as compared with SEK265.0m. Organic growth was 16 %.

Also, the company's board of directors has proposed a dividend of SEK1.50 per share for 2017, as compared with SEK1.50 per share, in 2016.

CellaVision develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services.